The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antibodies Can Spot RA in the General Population

Antibodies Can Spot RA in the General Population

May 9, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Anti-citrullinated protein antibodies (ACPA), particularly high anti-CCP2 titers, can diagnose rheumatoid arthritis (RA) in the general population with a high degree of accuracy, a Swedish study suggests.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • Bronchial Tissue Immune Activation Seen in Early Rheumatoid Arthritis
  • The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

ACPA are highly specific for RA, but until now the diagnostic accuracy of ACPA in the general population has not been “thoroughly assessed,” note Dr. Aase Haj Hensvold of the Karolinska Institutet, Stockholm, and colleagues in their April 28 Annals of the Rheumatic Diseases online report.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

They assessed the diagnostic accuracy of ACPA for RA in 12,590 population-representative Swedish twins. They analyzed serum samples for the presence of ACPA using anti-CCP2 enzyme-linked immunosorbent assay (ELISA) and all ACPA-positive samples were further tested on ELISAs for four peptide-specific ACPA. They identified patients with RA in the Swedish National Patient Register at inclusion and after a median of 37 months.

They report that 350 of all 12,590 individuals (2.8%) had a positive anti-CCP2 test, measuring ACPA, and 103 of these individuals (29.4%) had an RA diagnosis at the time of blood donation and inclusion. During follow-up, an additional 21 of the remaining 247 ACPA-positive individuals (8.5%) developed RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Overall, a positive anti-CCP2 test had a positive predictive value of 29% for prevalent RA at inclusion (negative predictive value of 99.6%),” the investigators report. High titers of anti-CCP2 (>3 times cut-off) increased the positive predictive value to 48% (negative predictive value of 99.5%), they note.

“ACPA-positive individuals without RA had lower anti-CCP2 titers and fewer peptide-specific ACPA than ACPA-positive patients with RA and higher C reactive protein levels than ACPA-negative individuals without RA,” they further report.

The investigators also note that, with more than 12,000 individuals in the study, it’s so far the largest to report on the diagnostic accuracy of ACPA and the results align with these previous reports showing a high specificity of anti-CCP2 for RA.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

They say the “lack of consecutive ACPA testing in same subjects is a limitation preventing estimation of the predictive values of variable ACPA status over time but will be an important task for future studies.”

“In conclusion, we have demonstrated that ACPA testing in a population-based setting has high specificity for prevalent RA. High anti-CCP titer entails better prediction for RA and is linked to multiple ACPA reactivities and higher CRP levels,” they write.

The study had no commercial funding. One author holds a patent protecting the use of CitC1 peptide. Dr. Hensvold did not respond to a request for comment by press time.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: ACPA, anti-citrullinated protein antibody (ACPA), Rheumatiod arthritis, screening, Testing

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • Bronchial Tissue Immune Activation Seen in Early Rheumatoid Arthritis
  • The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)
  • As Population Ages, Rheumatologists Prepare to Treat Elderly Patients with More Comorbidities

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.